Brief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
10/09/2026 21:18
BRIEF-Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027 Sept 10 (Reuters) - Lyell Immunopharma, Inc. LYEL.O:
LYELL IMMUNOPHARMA COMPLETES MANUFACTURING TRANSFER FOR LYL273 AND PROVIDES UPDATED TIMELINE ON PHASE 1/2 TRIAL IN METASTATIC COLORECTAL CANCER
LYELL IMMUNOPHARMA, - ADDITIONAL CLINICAL DATA AND END-OF-PHASE 1 FDA MEETING EXPECTED IN 2027
Source text: ID:nGNX2Pp3Pn
Further company coverage: LYEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma